Sanofi
Global biopharmaceutical company that uses additive manufacturing in pharmaceutical R&D (e.g., 3D-printed drug formulations, bioprinted tissue models) to advance personalized medicine and vaccine safety.
- CEO / Founder
- Belén Garijo
- Team Size
- 5001-10000
- Stage
- Public
- Latest Round
- Post-IPO
Technology & Products
Key Products
Prescription medicines; Vaccines; Consumer healthcare products
Technological Advantage
Sanofi's edge lies in pharmaceutical science; its AM initiatives (3D-printed medicines, bioprinted skin models) are experimental and not core to its business model. No proprietary AM technology or patents are publicly reported.
Differentiation
Value Proposition
Aims to improve health outcomes through innovative medicines and vaccines; internally uses 3D printing to accelerate drug development and enable personalized dosing.
How They Differentiate
Not applicable – Sanofi is a pharmaceutical company, not an additive manufacturing equipment, materials, software, or service provider.
Market & Competition
Target Customers
Patients, healthcare providers, and healthcare systems globally
Industry Verticals
Healthcare; Pharmaceuticals
Competitors
Amgen, Teva, Pfizer, Mylan, Sandoz, Roche, Abbott, Lilly, Merck, Medtronic, GSK, Bristol-Myers Squibb, Gilead Sciences, Viatris, AstraZeneca, AbbVie, Novartis, Novo Nordisk
Growth & Milestones
Growth Metrics
2025 sales growth of 10.3% in Q4; 2024 business EPS guidance of low double-digit growth at CER; revenue growth over past year 5.5%, two-year CAGR 5.9%.
Major Milestones
1973: Founded in Paris; 2004: Merged with Aventis to form Sanofi-Aventis; 2011: Renamed Sanofi; 2023: Launched Sanofi 3D Hub for internal manufacturing innovation; 2026: Belén Garijo appointed CEO
Funding rounds
- Post-IPOSource: Tracxn